These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32336418)

  • 1. Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Haddadin M; Taylor J
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):539-552. PubMed ID: 32336418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Hammond D; Pemmaraju N
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):565-574. PubMed ID: 32336420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A; Sweet K
    J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Kerr D; Zhang L; Sokol L
    Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blastic Plasmacytoid Dendritic Cell Neoplasm in Children.
    Li Y; Sun V; Sun W; Pawlowska A
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):601-612. PubMed ID: 32336423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
    Economides MP; Rizzieri D; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Kharfan-Dabaja MA; Cherry M
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
    Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Jen WY; Konopleva M; Pemmaraju N
    Cancer; 2024 Jul; 130(13):2260-2271. PubMed ID: 38620053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis.
    Deconinck E; Petrella T; Garnache Ottou F
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):491-500. PubMed ID: 32336414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Adimora IJ; Wilson NR; Pemmaraju N
    Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ; Wilson NR; Pemmaraju N
    Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
    Kerr D; Sokol L
    Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR; Pemmaraju N
    Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Lane AA
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):589-600. PubMed ID: 32336422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Alfayez M; Konopleva M; Pemmaraju N
    Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Xue T; Budde LE
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.